Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:AZTR NASDAQ:BLRX NASDAQ:HOOK OTCMKTS:INTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAZTRAzitra$0.21-4.2%$0.22$0.10▼$2.40$3.58M-1.29457,374 shs211,347 shsBLRXBioLineRx$3.37-2.9%$2.84$2.15▼$5.27$15.16M1.53107,899 shs51,218 shsHOOKHOOKIPA Pharma$1.15$1.15$0.81▼$1.65$14.18M0.8511,089 shs431 shsINTIInhibitor Therapeutics$0.08$0.08$0.04▼$0.12$14.76M-0.619,101 shsN/ATen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAZTRAzitra-4.21%+0.28%-2.35%+23.80%-88.65%BLRXBioLineRx-2.88%+4.33%+7.67%+28.14%-38.05%HOOKHOOKIPA Pharma0.00%0.00%-2.54%+7.48%-22.30%INTIInhibitor Therapeutics0.00%+10.21%-5.71%-3.57%+70.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAZTRAzitra$0.21-4.2%$0.22$0.10▼$2.40$3.58M-1.29457,374 shs211,347 shsBLRXBioLineRx$3.37-2.9%$2.84$2.15▼$5.27$15.16M1.53107,899 shs51,218 shsHOOKHOOKIPA Pharma$1.15$1.15$0.81▼$1.65$14.18M0.8511,089 shs431 shsINTIInhibitor Therapeutics$0.08$0.08$0.04▼$0.12$14.76M-0.619,101 shsN/ATen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAZTRAzitra-4.21%+0.28%-2.35%+23.80%-88.65%BLRXBioLineRx-2.88%+4.33%+7.67%+28.14%-38.05%HOOKHOOKIPA Pharma0.00%0.00%-2.54%+7.48%-22.30%INTIInhibitor Therapeutics0.00%+10.21%-5.71%-3.57%+70.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAZTRAzitra 3.00Buy$4.001,789.47% UpsideBLRXBioLineRx 2.00HoldN/AN/AHOOKHOOKIPA Pharma 0.00N/AN/AN/AINTIInhibitor Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AZTR, INTI, BLRX, and HOOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/20/2026BLRXBioLineRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAZTRAzitra$10K342.74N/AN/A$0.35 per share0.60BLRXBioLineRx$1.18M12.48N/AN/A$5.36 per share0.63HOOKHOOKIPA Pharma$9.35M1.52N/AN/A$4.25 per share0.27INTIInhibitor TherapeuticsN/AN/AN/AN/A($0.01) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAZTRAzitra-$10.95MN/AN/AN/AN/AN/A-251.51%-185.99%8/10/2026 (Estimated)BLRXBioLineRx-$1.17M-$1.92N/AN/AN/A-563.70%-37.73%-19.42%8/13/2026 (Estimated)HOOKHOOKIPA Pharma-$43.50M-$3.54N/AN/AN/A-785.66%-120.09%-77.14%8/7/2026 (Estimated)INTIInhibitor Therapeutics-$3.30M-$0.01N/AN/AN/AN/A-1,693.49%-122.07%N/ALatest AZTR, INTI, BLRX, and HOOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2026Q1 2026BLRXBioLineRx-$1.04-$0.36+$0.68-$0.36$0.34 million$0.48 million5/15/2026Q1 2026INTIInhibitor TherapeuticsN/A$999.00N/A$999.00N/AN/A5/13/2026Q1 2026AZTRAzitra-$0.01-$0.25-$0.24-$0.25N/AN/A3/25/2026Q4 2025INTIInhibitor TherapeuticsN/A-$0.01N/A-$0.01N/AN/A3/24/2026Q4 2025BLRXBioLineRx-$0.50-$0.34+$0.16N/A$0.49 million$0.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAZTRAzitraN/AN/AN/AN/AN/ABLRXBioLineRxN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/AINTIInhibitor TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAZTRAzitraN/A6.946.94BLRXBioLineRx0.161.581.43HOOKHOOKIPA PharmaN/A3.613.61INTIInhibitor TherapeuticsN/A3.603.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAZTRAzitra11.16%BLRXBioLineRx1.56%HOOKHOOKIPA Pharma63.88%INTIInhibitor TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAZTRAzitra0.28%BLRXBioLineRx1.10%HOOKHOOKIPA Pharma3.30%INTIInhibitor Therapeutics4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAZTRAzitra1016.19 million16.15 millionNot OptionableBLRXBioLineRx404.37 million4.32 millionOptionableHOOKHOOKIPA Pharma16012.33 million11.79 millionOptionableINTIInhibitor Therapeutics1173.79 million165.80 millionNot OptionableAZTR, INTI, BLRX, and HOOK HeadlinesRecent News About These CompaniesInhibitor Therapeutics Sues Investor Over Failed Financing DealApril 1, 2026 | tipranks.comInhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin SyndromeMarch 31, 2026 | markets.businessinsider.comInhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin SyndromeMarch 31, 2026 | globenewswire.comInsilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 InhibitorJanuary 24, 2026 | tmcnet.comInsilico agrees on $66M deal to split rights for preclinical NLRP3 inhibitor with new Chinese biotechJanuary 21, 2026 | fiercebiotech.comFNovel Small Molecule Inhibitors Show Efficacy in Endometrial CancerJanuary 11, 2026 | targetedonc.comTVaccines and Therapeutics Utilizing New Adjuvants and Potential Inhibitors to Target Emerging Infectious DiseasesDecember 2, 2025 | frontiersin.orgFPrelude Therapeutics to Pause Development of Cancer DrugNovember 4, 2025 | marketwatch.comBasal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsightOctober 27, 2025 | finance.yahoo.comCheckpoint Inhibitor Refractory Cancer Market CAGR to be at 11.5% | $56.64 Billion Industry Revenue by 2029September 10, 2025 | biznes.newseria.plBDPP1 Inhibitor Market Set to Reach New Heights in the Coming Decade | DelveInsightSeptember 9, 2025 | finance.yahoo.comJAK Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and CompaniesAugust 22, 2025 | theglobeandmail.comMCL1 Inhibitor Drugs Clinical Trials & Market Opportunity Report 2025: Over 12 ML1 Inhibitor Drugs In Clinical TrialsAugust 5, 2025 | finance.yahoo.comTissue Factor Pathway Inhibitor (TFPI) ELISA Kit Market Set to Reach US$ 301.0 Million by 2033 | Astute AnalyticaAugust 1, 2025 | finance.yahoo.comINTI Inhibitor Therapeutics, Inc.June 20, 2025 | seekingalpha.comEli Lilly lands next-gen pain asset in SiteOne Therapeutics acquisition worth up to $1BMay 27, 2025 | fiercebiotech.comFDeep Dive: Checkpoint Inhibitors at a CrossroadsMay 19, 2025 | biospace.comBSterol 14 Alpha-Demethylase Inhibitor: 2025 Pipeline Therapeutics Landscape and Growth ProspectsMay 8, 2025 | uk.finance.yahoo.comRAGE Inhibitor Pipeline Insight Report 2025 Analyzes RAGE Inhibitor Drugs, Key Players, and Development ActivitiesApril 30, 2025 | finance.yahoo.comFirst-in-class, oral small-molecule SERCA inhibitor for synucleinopathiesApril 23, 2025 | bioworld.comBNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026These 3 CLO ETFs Target a Niche Corner of the Fixed-Income MarketBy Nathan Reiff | May 31, 2026NVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingBy Thomas Hughes | May 21, 2026AZTR, INTI, BLRX, and HOOK Company DescriptionsAzitra NYSEAMERICAN:AZTR$0.21 -0.01 (-4.21%) Closing price 06/12/2026 04:10 PM EasternExtended Trading$0.21 +0.00 (+0.14%) As of 06/12/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.BioLineRx NASDAQ:BLRX$3.37 -0.10 (-2.88%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$3.39 +0.02 (+0.59%) As of 06/12/2026 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.HOOKIPA Pharma NASDAQ:HOOK$1.15 0.00 (0.00%) As of 06/2/2026HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Inhibitor Therapeutics OTCMKTS:INTI$0.08 0.00 (0.00%) As of 06/11/2026Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
